MedTrace Logo

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

NCT01329185 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2019-11-01

Study results available
· View outcomes & findings →

Summary

The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the prevention of AIDS and so along the same lines the investigators will test the hypothesis that 14 days of the anti-viral Valganciclovir (VAL) to kidney donors prior to the transplant compared to placebo will reduce EBV and CMV viremia in the 1st year posttransplant in pediatric kidney recipients.

Conditions

  • EBV Viremia
  • CMV Viremia

Interventions

DRUG

Valganciclovir

Valganciclovir 450mg twice a day for 14 days prior to transplant date

DRUG

Placebo

1 capsule twice a day for 14 days prior to transplant date

Sponsors & Collaborators

Principal Investigators

  • Priya Verghese, MD, MPH · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01329185 on ClinicalTrials.gov